Literature DB >> 18784147

Renal manifestations of systemic sclerosis--clinical features and outcome assessment.

C P Denton1.   

Abstract

Renal manifestations occur frequently in scleroderma (SSc). Commonest is a reduction in renal function due to chronic disease but most clinically important is the scleroderma renal crisis (SRC). This life-threatening complication occurs in up to 15% of the cases of dcSSc. Mortality is reduced by use of angiotensin converting enzyme (ACE) inhibitors. Renal outcome can be assessed by quantifying renal function, measuring proteinuria, exploring the frequency of renal crisis episodes and through assessment of renal outcome following SRC-such as frequency and duration of dialysis, or recovery of renal function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784147     DOI: 10.1093/rheumatology/ken307

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  Renal disease in systemic sclerosis with normal serum creatinine.

Authors:  Reem H A Mohamed; Hania S Zayed; Amr Amin
Journal:  Clin Rheumatol       Date:  2010-02-23       Impact factor: 2.980

2.  Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis.

Authors:  Predrag Ostojic; Natasa Stojanovski
Journal:  Rheumatol Int       Date:  2016-12-22       Impact factor: 2.631

Review 3.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 4.  Cardiac manifestations in systemic sclerosis.

Authors:  Sevdalina Lambova
Journal:  World J Cardiol       Date:  2014-09-26

Review 5.  Corticosteroids and the risk of scleroderma renal crisis: a systematic review.

Authors:  Gerald Trang; Russell Steele; Murray Baron; Marie Hudson
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

6.  Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

Authors:  Chitra Hosing; Richard Nash; Peter McSweeney; Shin Mineishi; James Seibold; Linda M Griffith; Howard Shulman; Ellen Goldmuntz; Maureen Mayes; Chirag R Parikh; Leslie Crofford; Lynette Keyes-Elstein; Daniel Furst; Virginia Steen; Keith M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-11       Impact factor: 5.742

7.  N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis.

Authors:  Edoardo Rosato; Rosario Cianci; Biagio Barbano; Ginevra Menghi; Antonietta Gigante; Carmelina Rossi; Enrico M Zardi; Antonio Amoroso; Simonetta Pisarri; Felice Salsano
Journal:  Acta Pharmacol Sin       Date:  2009-09       Impact factor: 6.150

Review 8.  Endothelins in cardiovascular biology and therapeutics.

Authors:  Neeraj Dhaun; David J Webb
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

9.  Scleroderma Renal Crisis in a Normotensive Patient.

Authors:  Efua Asamoah-Odei
Journal:  Kidney Int Rep       Date:  2016-07-25

10.  Renal pathology and clinical associations in systemic sclerosis: a historical cohort study.

Authors:  Pantipa Tonsawan; Komkid Talabthong; Anucha Puapairoj; Chingching Foocharoen
Journal:  Int J Gen Med       Date:  2019-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.